Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Symptom control, daily "on" time, and quality of life (QoL) of nine patients with Advanced Parkinson's Disease was assessed following 18-months treatment with Continuous Intraduodenal Levodopa Infusion (CIDLI). Patients had severe motor fluctuations and dyskinesias and had previously received treatment with oral levodopa and dopamine agonists. There were significant improvements in patients' symptoms on the Unified Parkinson's Disease Rating Scale, and QoL (Parkinson's Disease QoL Questionnaire; Schwab & England Capacity for Daily Living Scale; p < 0.05). Mean (+/-SD) daily "on" time increased from 6.1 +/- 1.9 to 12.0 +/- 3.4 h (p < 0.05). Improved QoL in APD was associated with CIDLI-related improvements in symptom control and increase in daily "on" time.
Puente
V
V
Neurology Department, Institut Municipal d'Investigacio Medica, Universitat Autonoma de Barcelona, Hospital del Mar, Barcelona, Spain. 93199@imas.imim.es
De Fabregues
O
O
Oliveras
C
C
Ribera
G
G
Pont-Sunyer
C
C
Vivanco
R
R
Cucurella
G
G
Giralt
E
E
Delgado
T
T
Garcia
C
C
Seoane
A
A
Campo
R
R
D000203:Activities of Daily Living; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D004185:Disability Evaluation; D004386:Duodenum / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology*; D011788:Quality of Life; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D007980:Levodopa